These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9443644)

  • 1. Piperazine derivatives of butyric acid as differentiating agents in human leukemic cells.
    Gillet R; Jeannesson P; Sefraoui H; Arnould-Guérin ML; Kirkiacharian S; Jardillier JC; Pieri F
    Cancer Chemother Pharmacol; 1998; 41(3):252-5. PubMed ID: 9443644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Derivatives of butyric acid as potential anti-neoplastic agents.
    Rephaeli A; Rabizadeh E; Aviram A; Shaklai M; Ruse M; Nudelman A
    Int J Cancer; 1991 Aug; 49(1):66-72. PubMed ID: 1874573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60.
    Breitman TR; He RY
    Cancer Res; 1990 Oct; 50(19):6268-73. PubMed ID: 2400989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy.
    Chen ZX; Breitman TR
    Cancer Res; 1994 Jul; 54(13):3494-9. PubMed ID: 8012972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child.
    Novogrodsky A; Dvir A; Ravid A; Shkolnik T; Stenzel KH; Rubin AL; Zaizov R
    Cancer; 1983 Jan; 51(1):9-14. PubMed ID: 6571794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells.
    Kasukabe T; Rephaeli A; Honma Y
    Br J Cancer; 1997; 75(6):850-4. PubMed ID: 9062406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel anticancer prodrugs of butyric acid. 2.
    Nudelman A; Ruse M; Aviram A; Rabizadeh E; Shaklai M; Zimrah Y; Rephaeli A
    J Med Chem; 1992 Feb; 35(4):687-94. PubMed ID: 1542095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukaemia cells.
    Santini V; Scappini B; Gozzini A; Grossi A; Villa P; Ronco G; Douillet O; Pouillart P; Bernabei PA; Rossi Ferrini P
    Br J Haematol; 1998 Jun; 101(3):529-38. PubMed ID: 9633898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential clinical use of butyric acid derivatives to induce antigen-specific T cell inactivation.
    Gilbert KM; Wahid R; Fecher NP; Freeman JP; Fifer EK
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1146-53. PubMed ID: 10945871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New stable butyrate derivatives alter proliferation and differentiation in human mammary cells.
    Planchon P; Raux H; Magnien V; Ronco G; Villa P; Crépin M; Brouty-Boyé D
    Int J Cancer; 1991 May; 48(3):443-9. PubMed ID: 2040538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase.
    Lea MA; Tulsyan N
    Anticancer Res; 1995; 15(3):879-83. PubMed ID: 7645975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship of 17 structural analogues of n-butyric acid upon c-myc expression.
    Rottleb C; Hall C; Bornkamm GW; Polack A
    Int J Cancer; 1996 Sep; 67(5):724-9. PubMed ID: 8782665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of sublines of HL-60 human leukemia cells resistant to induction of differentiation by butyric acid.
    Fischkoff SA; Hoessly MC; Rossi RM
    Leukemia; 1990 Apr; 4(4):302-6. PubMed ID: 2164121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Butyric monosaccharide ester-induced cell differentiation and anti-tumor activity in mice. Importance of their prolonged biological effect for clinical applications in cancer therapy.
    Pouillart P; Cerutti I; Ronco G; Villa P; Chany C
    Int J Cancer; 1991 Aug; 49(1):89-95. PubMed ID: 1874576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
    Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
    Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human immunodeficiency virus(HIV) inhibitor 9-(2-phosphonylmethoxyethyl)adenine (PMEA) is a strong inducer of differentiation of several tumor cell lines.
    Balzarini J; Verstuyf A; Hatse S; Goebels J; Sobis H; Vandeputte M; De Clercq E
    Int J Cancer; 1995 Mar; 61(1):130-7. PubMed ID: 7705926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure-activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells.
    Kim HH; Sik Bang S; Seok Choi J; Han H; Kim IH
    Cancer Lett; 2005 Jun; 223(2):191-201. PubMed ID: 15896453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of herbimycin A derivatives on growth and differentiation of K562 human leukemic cells.
    Honma Y; Kasukabe T; Hozumi M; Shibata K; Omura S
    Anticancer Res; 1992; 12(1):189-92. PubMed ID: 1567167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line.
    Aviram A; Zimrah Y; Shaklai M; Nudelman A; Rephaeli A
    Int J Cancer; 1994 Mar; 56(6):906-9. PubMed ID: 8119779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative and erythroid differentiation of piperazine and triphenyl derivatives against k-562 human chronic myelogenous leukemia.
    Saab AM; Dobmeier M; Koenig B; Fabri E; Finotti A; Borgatti M; Lampronti I; Bernardi F; Efferth T; Gambari R
    Anticancer Res; 2013 Aug; 33(8):3027-32. PubMed ID: 23898056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.